Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Celgene, Nurix Target Protein Homeostasis for Next-Gen Therapies | Contract Pharma

What are you searching for?

Sign in
Breaking News

Celgene, Nurix Target Protein Homeostasis for Next-Gen Therapies

To develop small molecule therapeutics in oncology, inflammation and immunology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nurix, Inc. has entered into a strategic collaboration with Celgene Corp. for the discovery, development and commercialization of novel small molecule therapeutics in oncology, inflammation and immunology, including immuno-oncology. The companies will work to advance new therapies that function through the ubiquitin proteasome system (UPS) to modulate protein homeostasis, a fundamental cellular process controlling protein levels. Mutations in UPS genes are common drivers of many human cancers.
 
Nurix will receive $150 million, plus an undisclosed equity investment, for an option to license future programs. Nurix is responsible for all drug discovery and development activities through Phase I trials.
 
Celgene may license global development and commercialization rights to a program in exchange for an option fee, potential clinical, regulatory and sales milestones totaling as much as $405 million, as well as future royalties. Celgene will have worldwide rights to collaboration products, with the exception of certain products for which Nurix retains U.S. development and commercialization rights.
 
“Given its global leadership position in the UPS field, Celgene is the ideal partner for Nurix to fully realize the potential of our unique drug discovery engine for small molecule activators and inhibitors of E3 ubiquitin ligases and E2 conjugating enzymes,” said Arthur T. Sands, chief executive officer of Nurix. “With a shared vision to create a new class of drugs that work by selectively modulating cellular protein levels, we have designed a transformative collaboration that empowers Nurix to move its pipeline from discovery through development and commercialization. We look forward to working with Celgene, the pre-eminent company in development and commercialization of therapies targeting the UPS.”
 
“Consistent with our deep commitment and competitive position in the arena of protein homeostasis, we are excited to initiate this collaboration with the exceptional team that Nurix has assembled. This collaboration extends our approach in the E3 ubiquitin ligase space, and provides a highly complementary effort addressing important targets in oncology and immune-inflammatory diseases,” said Thomas Daniel, M.D., president, Global R&D at Celgene.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics